Zogenix, Inc. ZGNX
today announced an update on its development programs focused on the
introduction of abuse deterrent formulations of Zohydro(R) ER (hydrocodone
bitartrate) Extended-Release Capsules, CII. Zohydro ER is indicated for the
management of pain severe enough to require daily, around-the-clock,
long-term opioid treatment and for which alternative treatment options are
inadequate. The company has previously indicated that it is simultaneously
developing two distinct approaches for abuse deterrent formulations of
Zohydro ER. Following a recent meeting with the U.S. Food and Drug
Administration (FDA), Zogenix expects to file a supplemental new drug
application (sNDA) by October 2014 for a next-generation formulation of
Zohydro ER Extended-Release Capsules designed to make it more difficult to
abuse by injection or nasal administration.
If approved, this new formulation could be available to prescribers in early
2015. The company will continue to characterize the product's abuse
deterrent properties with the goal of further amending the labeling for
Zohydro ER Extended-Release Capsules in 2015 to include abuse deterrence
claims consistent with the FDA's current draft Guidance for Industry,
Abuse-Deterrent Opioids -- Evaluation and Labeling. As of today, only one of
more than thirty extended-release/long-acting opioid analgesics has abuse
deterrent properties described in FDA-approved labeling for making abuse via
injection more difficult and reducing abuse via the nasal route based on the
draft Guidance for Industry.
Zogenix also recently selected the final tablet formulation for clinical
development in its collaboration with Altus Formulation. Like the
next-generation formulation, this proprietary tablet technology is designed
to meet FDA's stated goal of encouraging scientific and clinical research
that will advance the development of abuse deterrent technologies to address
opioid medication misuse and abuse. The innovative tablet formulation of
Zohydro ER incorporates multiple features to maintain the extended-release
property of the medication when crushed or chewed, reducing one of the ways
in which opioids are abused through oral ingestion, as well other features
to address abuse by injection or nasal administration.
The company is targeting a new drug application (NDA) submission for this
tablet formulation during the first half of 2016, which will reference the
approved NDA for Zohydro ER with respect to previous findings of safety and
efficacy. The tablet formulation is designed to have the same hydrocodone
release profile as the currently approved capsule formulation of Zohydro ER
when used as intended, greatly simplifying its development program.
"We believe we have two strong technology options to deter misuse and abuse
without affecting the established safety and efficacy profile of Zohydro ER,
and look forward to submitting our data to the FDA with the goal of bringing
these new options to patients," said Stephen Farr, Ph.D., President of
Zogenix. "This dual approach will allow us to potentially launch our next
generation of Zohydro ER Extended-Release Capsules in early 2015, followed
by the tablet formulation with advanced proprietary abuse deterrent
technology in 2016. We also continue to take part in comprehensive and
collaborative efforts with prescribers, pharmacists and government officials
to help ensure appropriate patients have access to the medications that will
best support the management of their severe chronic pain."
In addition to working with FDA to integrate abuse deterrent properties into
Zohydro ER, Zogenix strongly supports more comprehensive approaches to
addressing the public health challenge of prescription drug abuse. Zogenix
has taken extraordinary steps to support the appropriate use of Zohydro ER
through a voluntary set of educational tools and safeguards to augment the
FDA industry mandated class-wide Risk Evaluation Mitigation Strategy (REMS)
for extended-release opioids. The company has implemented novel initiatives,
such as providing Zohydro ER patients free locking pill bottle caps and
discounts for safe-storage units to help prevent other people from gaining
access to their medications. Prior to the availability of Zohydro ER,
Zogenix established an independent External Safe Use Board to assess and
make recommendations on surveillance programs and data collection related to
misuse and diversion of the product.
Approved by the FDA in October 2013, Zohydro ER provides a potential
solution to patients who could benefit from an extended-release hydrocodone
for around-the clock management of severe chronic pain and who may be at
risk for liver damage due to overexposure of acetaminophen, which can be
fatal or require a liver transplant.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in